Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.
Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).
2001
Served areaWorldwide
HeadquartersScheelevägen 2, 22381 Lund – Sweden
221,534,728
IPOJan. 1, 2000
Stock exchange(s)Nasdaq Stockholm